Aveanna Healthcare (AVAH) raises 2026 guidance as Q2 revenue hits $670.5M
Rhea-AI Filing Summary
Aveanna Healthcare Holdings Inc. reported strong growth for the three and six-month periods ended July 4, 2026. For the quarter, revenue was $670.5 million, up 13.7% from $589.6 million a year earlier, driven by increases across its PDS, HHH, and MS segments. Quarterly net income rose to $40.3 million (diluted EPS $0.18) from $27.0 million (EPS $0.13), while Adjusted EBITDA was $95.4 million, up 8.0%, although the Adjusted EBITDA margin declined to 14.2% from 15.0% as gross margin percentage compressed.
For the first six months, revenue reached $1,318.4 million, an increase of 14.8%, with net income of $81.9 million versus $32.2 million and Adjusted EBITDA of $179.8 million, up 15.4%. Aveanna raised its full-year 2026 outlook, guiding to revenue of more than $2.68 billion and Adjusted EBITDA of more than $365 million. As of July 4, 2026, the company held $97.2 million of cash and $1,483.4 million of total indebtedness, with additional borrowing capacity under its securitization facility and revolving credit facility.
Positive
- Q2 2026 revenue grew 13.7% to $670.5 million, with all three segments (PDS, HHH, MS) contributing to the increase.
- Profitability improved: Q2 net income rose to $40.3 million from $27.0 million, and six-month net income to $81.9 million from $32.2 million.
- The company raised full-year 2026 guidance to revenue of more than $2.68 billion and Adjusted EBITDA of more than $365 million.
- Operating cash flow strengthened, with net cash provided by operating activities of $85.3 million and free cash flow of $75.4 million for the first six months of 2026.
Negative
- Margins compressed: Q2 gross margin percentage declined to 32.6% from 35.8%, and field contribution margin fell to 18.1% from 20.5%.
- Aveanna remains highly leveraged, reporting total indebtedness of $1,483.4 million as of July 4, 2026.
- Net cash used in investing activities increased significantly to $179.9 million for the first six months of 2026 compared with $18.3 million in the prior-year period.
Filing Explained
As of July 4, cash was $97.2 million; stated capacity was $110.0 million under securitization and approximately $225.5 million on the revolver.
This Form 8-K reports a specified material event and furnishes the company’s August 13, 2026 results release under Items 2.02 and 7.01, rather than filing that information.
The furnished information is not subject to Section 18 liabilities and cannot be incorporated by reference into another Exchange Act or Securities Act filing unless that filing specifically incorporates it.
As of
For the six months ended
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
Free cash flow financial
Field contribution financial
securitization facility financial
interest rate caps financial
Earnings Snapshot
For full-year 2026, Aveanna guides to revenue of greater than $2.68 billion and Adjusted EBITDA of greater than $365 million.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Aveanna Healthcare (AVAH) perform financially in Q2 2026?
What are Aveanna Healthcare’s (AVAH) updated full-year 2026 guidance targets?
How did Aveanna Healthcare’s (AVAH) profitability and margins change year over year?
What is Aveanna Healthcare’s (AVAH) debt and liquidity position as of July 4, 2026?
How strong was Aveanna Healthcare’s (AVAH) cash flow in the first half of 2026?
Which segments drove Aveanna Healthcare’s (AVAH) revenue growth in Q2 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
(Address of Principal Executive Offices) |
(Zip Code) |
(
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 13, 2026, Aveanna Healthcare Holdings Inc., a Delaware corporation (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the three and six-month periods ended July 4, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.
Item 7.01 Regulation FD Disclosure.
The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.
The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
99.1 |
|
Press Release dated August 13, 2026 announcing the Company’s financial results for the three and six-month periods ended July 4, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AVEANNA HEALTHCARE HOLDINGS INC. |
|
|
|
|
|
Date: August 13, 2026 |
|
By: |
/s/ Deborah Stewart |
|
|
|
Deborah Stewart |
|
|
|
Chief Accounting Officer (Principal Accounting Officer) |
Exhibit 99.1
AVEANNA HEALTHCARE HOLDINGS ANNOUNCES SECOND
QUARTER FINANCIAL RESULTS AND REVISED 2026 GUIDANCE
Atlanta, Georgia (August 13, 2026) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and six-month periods ended July 4, 2026.
Jeff Shaner, Chief Executive Officer, commented, “Our second quarter results demonstrate the momentum across Aveanna and our ability to consistently deliver sustained year-over-year growth. Revenue and Adjusted EBITDA increased 13.7% and 8.0%, respectively, compared to the prior-year period, reflecting our strong organic growth across all three business segments. Our results reinforce the strength of our operating model, the continued success of our Preferred Payor and Government Affairs strategies, and the dedication of our team to deliver exceptional care to patients and families. Given our performance in the first half of the year and confidence in our outlook, we are pleased to raise our 2026 revenue and Adjusted EBITDA guidance.”
Three-Month Periods Ended July 4, 2026 and June 28, 2025
Revenue was $670.5 million for the three-month period ended July 4, 2026, as compared to $589.6 million for the three-month period ended June 28, 2025, an increase of $80.9 million, or 13.7%. The overall increase in revenue was attributable to a $67.9 million increase in PDS segment revenue, an $8.9 million increase in HHH segment revenue, and a $4.1 million increase in MS segment revenue compared to the second quarter of 2025.
Gross margin was $218.5 million, or 32.6% of revenue, for the three-month period ended July 4, 2026, as compared to $210.8 million, or 35.8% of revenue, for the three-month period ended June 28, 2025, an increase of $7.7 million, or 3.7%.
Net income was $40.3 million or 6.0% of revenue, for the three-month period ended July 4, 2026, as compared to net income of $27.0 million, or 4.6% of revenue for the three-month period ended June 28, 2025. Net income per diluted share was $0.18 for the three-month period ended July 4, 2026, as compared to net income per diluted share of $0.13 for the three-month period ended June 28, 2025. Adjusted net income per diluted share was $0.22 for the three-month period ended July 4, 2026, as compared to adjusted net income per diluted share of $0.18 for the three-month period ended June 28, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.
Adjusted EBITDA was $95.4 million, or 14.2% of revenue, for the three-month period ended July 4, 2026, as compared to $88.4 million, or 15.0% of revenue, for the three-month period ended June 28, 2025, an increase of $7.1 million or 8.0%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.
Six-Month Periods Ended July 4, 2026 and June 28, 2025
1
Revenue was $1,318.4 million for the six-month period ended July 4, 2026, as compared to $1,148.8 million for the six-month period ended June 28, 2025, an increase of $169.6 million, or 14.8%. The overall increase in revenue was attributable to a $143.6 million increase in PDS segment revenue, an $18.8 million increase in HHH segment revenue, and a $7.3 million increase in MS segment revenue compared to the first six months of 2025.
Gross margin was $424.0 million, or 32.2% of revenue, for the six-month period ended July 4, 2026, as compared to $394.4 million, or 34.3% of revenue, for the six-month period ended June 28, 2025, an increase of $29.6 million, or 7.5%.
Net income was $81.9 million or 6.2% of revenue for the six-month period ended July 4, 2026, as compared to net income of $32.2 million or 2.8% of revenue for the six-month period ended June 28, 2025. Net income per diluted share was $0.37 for the six-month period ended July 4, 2026, as compared to net income per diluted share of $0.16 for the six-month period ended June 28, 2025. Adjusted net income per diluted share was $0.40 for the six-month period ended July 4, 2026, as compared to adjusted net income per diluted share of $0.28 for the six-month period ended June 28, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.
Adjusted EBITDA was $179.8 million, or 13.6% of revenue, for the six-month period ended July 4, 2026, as compared to $155.7 million, or 13.6% of revenue, for the six-month period ended June 28, 2025, an increase of $24.1 million or 15.4%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.
Liquidity, Cash Flow, and Debt
Matt Buckhalter, Chief Financial Officer, commented “Aveanna's second quarter results continued our momentum with our team executing at a high level across all three divisions. During the quarter, we delivered revenue of $670.5 million and Adjusted EBITDA of $95.4 million. These results, combined with the acquisition of Family First and the successful repricing of our credit facility demonstrate the strength of our platform and our commitment to sustainable growth while delivering high-quality care to the patients and families we serve. Our increased 2026 guidance, including revenue of greater than $2.68 billion and Adjusted EBITDA of greater than $365 million, underscores the strength of our business model and the opportunities ahead as we continue to execute on our strategic initiatives.”
Full Year 2026 Guidance
The following is our guidance reflecting our increased expectations for revenue and Adjusted EBITDA for the full fiscal year 2026 (year ending January 2, 2027):
Consistent with prior practice, we are not providing guidance on net income at this time due to the volatility of certain required inputs that are not available without unreasonable efforts, including future fair value adjustments associated with our interest rate caps.
Non-GAAP Financial Measures
In addition to our results of operations prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), we also evaluate our financial performance using EBITDA, Adjusted EBITDA, Field contribution, Field contribution margin, Adjusted net income or loss, Adjusted net income or loss per diluted share, and Free cash flow. Given our determination of adjustments in arriving at our computations, these non-GAAP measures have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to net income or loss, revenue, operating income or loss, cash flows from operating activities, total
2
indebtedness, gross margin, gross margin percentage or any other financial measures calculated in accordance with GAAP. The reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in the financial tables below.
EBITDA and Adjusted EBITDA
EBITDA and Adjusted EBITDA are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with GAAP, such as net income or loss. Rather, we present EBITDA and Adjusted EBITDA as supplemental measures of our performance. We define EBITDA as net income or loss before interest expense, net; income tax expense or benefit; and depreciation and amortization. We define Adjusted EBITDA as EBITDA, adjusted for the impact of certain other items that are either non-recurring, infrequent, non-cash, unusual, or items deemed by management to not be indicative of the performance of our core operations, including impairments of goodwill, intangible assets, and other long-lived assets; non-cash, share-based compensation and associated employer payroll taxes; loss on extinguishment of debt; fees related to debt modifications; the effect of interest rate derivatives; acquisition-related and integration costs; legal costs and settlements associated with acquisition matters; restructuring costs; other legal matters; and other system transition costs, professional fees and other costs. As non-GAAP financial measures, our computations of EBITDA and Adjusted EBITDA may vary from similarly termed non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of this measure impracticable.
We believe our computations of EBITDA and Adjusted EBITDA are helpful in highlighting trends in our core operating performance. In determining which adjustments are made to arrive at EBITDA and Adjusted EBITDA, we consider both (1) certain non-recurring, infrequent, non-cash or unusual items, which can vary significantly from year to year, as well as (2) certain other items that may be recurring, frequent, or settled in cash but which we do not believe are indicative of our core operating performance. We use EBITDA and Adjusted EBITDA to assess operating performance and make business decisions.
We have incurred substantial acquisition-related costs and integration costs. The underlying acquisition activities take place over a defined timeframe, have distinct project timelines and are incremental to activities and costs that arise in the ordinary course of our business. Therefore, we believe it is important to exclude these costs from our Adjusted EBITDA because it provides us a normalized view of our core, ongoing operations after integrating our acquired companies, which we believe is an important measure in assessing our performance.
Field contribution and Field contribution margin
Field contribution and Field contribution margin are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with GAAP, such as gross margin and gross margin percentage. Rather, we present Field contribution and Field contribution margin as supplemental measures of our performance. We define Field contribution as gross margin less branch and regional administrative expenses. Field contribution margin is Field contribution as a percentage of revenue. As non-GAAP financial measures, our computations of Field contribution and Field contribution margin may vary from similarly termed non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of these measures impracticable.
Field contribution and Field contribution margin have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to gross margin, gross margin percentage, net income or loss, revenue, operating income or loss, cash flows from operating activities, total indebtedness or any other financial measures calculated in accordance with GAAP.
Management believes Field contribution and Field contribution margin are helpful in highlighting trends in our core operating performance and evaluating trends in our branch and regional results, which can vary from year to year. We use Field contribution and Field contribution margin to make business decisions and assess the operating performance and results delivered by our core field operations, prior to corporate and other costs not directly related to our field operations. These metrics are also important because they guide us in determining whether or not our branch and regional administrative expenses are appropriately sized to support our caregivers and direct patient care operations. Additionally, Field contribution and Field contribution margin determine how effective we are in managing our field supervisory and administrative costs associated with supporting our provision of services and sale of products.
Adjusted net income and Adjusted net income per diluted share
Adjusted net income represents net income as adjusted for the impact of GAAP income tax, goodwill, intangible and other long-lived asset impairment charges, non-cash share-based compensation expense, loss on extinguishment of debt, fees related to debt modifications; interest rate derivatives, acquisition-related costs, integration costs, legal costs, restructuring costs, other legal matters, other system transition costs, professional fees and certain other miscellaneous items on a pre-tax basis. Adjusted net income includes a provision for income taxes derived utilizing a combined statutory tax rate. The combined statutory tax rate is our estimate of our long-term tax rate. The most comparable GAAP measure is net income.
3
Adjusted net income per diluted share represents adjusted net income on a per diluted share basis using the weighted-average number of diluted shares outstanding for the period. The most comparable GAAP measure is net income per share, diluted.
Adjusted net income and adjusted net income per diluted share are important to us because they allow us to assess financial results, exclusive of the items mentioned above that are not operational in nature or comparable to those of our competitors.
Free cash flow
Free cash flow is a liquidity measure that represents operating cash flow, adjusted for the impact of purchases of property, equipment and software, proceeds from issuance of term loans, net of debt issuance costs, principal payments on term loans, notes payable and financing leases, and settlements with swap counterparties. The most comparable GAAP measure is cash flow from operations.
We believe free cash flow is helpful in highlighting the cash generated or used by the Company, after taking into consideration mandatory payments on term loans, notes payable and financing leases, as well as cash needed for non-acquisition related capital expenditures, and cash paid to or received from derivative counterparties.
Conference Call
Aveanna will host a conference call on Thursday, August 13, 2026, at 10:00 a.m. Eastern Time to discuss our second quarter results. The conference call can be accessed live over the phone by dialing 1-877-407-0789, or for international callers, 1-201-689-8562. A telephonic replay of the conference call will be available until August 20, 2026, by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13760758. A live webcast of our conference call will also be available under the Investor Relations section of our website: https://ir.aveanna.com/. The online replay will also be available for one week following the call.
Forward-Looking Statements
Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “would,” “predict,” “project,” “potential,” “continue,” “could,” “design,” “guidance,” or the negatives of these terms or variations of them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, such as intense competition among home health, hospice and durable medical equipment companies; our ability to maintain relationships with existing patient referral sources; our ability to have services funded from third-party payers, including Medicare, Medicaid and private health insurance companies, including as a result of changes to Medicaid to be implemented under the One Big Beautiful Bill Act; changes to Medicare or Medicaid rates or methods governing Medicare or Medicaid payments, and the implementation of alternative payment models, including but not limited to Medicare Advantage, Managed Care Organization, managed Medicaid, and other forms of managed care; any downward pressure on reimbursement resulting from further proliferation of Medicare Advantage plans; our limited ability to control reimbursement rates received for our services; delays in collection or non-collection of our patient accounts receivable, particularly during the business integration process, or when transitioning between systems associated with clinical data collection and submission, as well as billing and collection systems; healthcare reform and other regulations, including risks related to the proposed rule issued for the home health prospective payment system by Centers for Medicare & Medicaid Services; changes in the case-mix of our patients, as well as payer mix and payment methodologies; any reduction in net reimbursement if we do not effectively implement value-based care programs; the possibility that our business, financial condition and results of operations may be materially adversely affected by public health emergencies, such as a pandemic or other infectious disease outbreak; shortages in qualified employees and management and competition for qualified personnel; any failure to maintain the security and functionality of our information systems or to defend against or otherwise prevent a cybersecurity attack or breach; our substantial indebtedness, which increases our vulnerability to general adverse economic and industry conditions and may limit our ability to pursue strategic alternatives and react to changes in our business and industry; our ability to identify, obtain financing for, acquire and integrate strategic and accretive businesses or assets; risks related to legal proceedings, claims and governmental inquiries given that the nature of our business exposes us to various liability claims, which may exceed the level of our insurance coverage, and other risks set forth under the heading “Risk Factors” in Aveanna’s Annual Report on Form 10-K for its 2025 fiscal year filed with the Securities and Exchange Commission on March 19, 2026, which is available at www.sec.gov. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this press release do not purport to be predictions of future events or circumstances, and actual results
4
may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
About Aveanna Healthcare
Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 39 states providing a broad range of pediatric and adult healthcare services, primarily focused on care in the home, including nursing, hospice, rehabilitation, occupational nursing in schools, therapy, and day treatment center services for medically complex and chronically ill children and adults, as well as delivery of enteral nutrition and other products to patients. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization. For more information, please visit www.aveanna.com.
5
Cash Flow and Information about Indebtedness
The following table sets forth a summary of our cash flows from operating, investing, and financing activities for the periods presented:
|
For the six-month periods ended |
|
|||||
(dollars in thousands) |
July 4, 2026 |
|
|
June 28, 2025 |
|
||
Net cash provided by operating activities |
$ |
85,277 |
|
|
$ |
42,937 |
|
Net cash used in investing activities |
$ |
(179,924 |
) |
|
$ |
(18,330 |
) |
Net cash used in financing activities |
$ |
(1,417 |
) |
|
$ |
(8,157 |
) |
Cash and cash equivalents at beginning of period |
$ |
193,260 |
|
|
$ |
84,288 |
|
Cash and cash equivalents at end of period |
$ |
97,196 |
|
|
$ |
100,738 |
|
The following table presents our long-term indebtedness as of July 4, 2026:
(dollars in thousands) |
|
|
|
|
|
Instrument |
Interest Rate |
|
July 4, 2026 |
|
|
2026 Term Loans (1) |
S + 3.00% |
|
$ |
1,318,375 |
|
2026 Refinancing Revolving Credit Facility (1) |
S + 3.00% |
|
|
- |
|
Securitization Facility (1) |
S + 2.50% |
|
|
165,000 |
|
Total indebtedness |
|
|
$ |
1,483,375 |
|
(1) S = One-month SOFR |
|
|
|
|
|
|
|
|
|
|
|
Results of Operations
The following table summarizes our consolidated results of operations for the periods indicated (amounts in thousands, except per share data):
|
For the three-month periods ended |
|
For the six-month periods ended |
|
||||||||
|
July 4, 2026 |
|
June 28, 2025 |
|
July 4, 2026 |
|
June 28, 2025 |
|
||||
Revenue |
$ |
670,483 |
|
$ |
589,553 |
|
$ |
1,318,398 |
|
$ |
1,148,777 |
|
Cost of revenue, excluding depreciation and amortization |
|
451,958 |
|
|
378,753 |
|
|
894,445 |
|
|
754,419 |
|
Branch and regional administrative expenses |
|
97,079 |
|
|
90,069 |
|
|
192,871 |
|
|
181,456 |
|
Corporate expenses |
|
34,083 |
|
|
34,529 |
|
|
68,239 |
|
|
72,034 |
|
Depreciation and amortization |
|
2,849 |
|
|
2,617 |
|
|
5,893 |
|
|
5,211 |
|
Acquisition-related costs |
|
4,390 |
|
|
3,400 |
|
|
7,500 |
|
|
3,506 |
|
Other operating expense |
|
144 |
|
|
151 |
|
|
144 |
|
|
316 |
|
Operating income |
|
79,980 |
|
|
80,034 |
|
|
149,306 |
|
|
131,835 |
|
Interest income |
|
1,259 |
|
|
129 |
|
|
2,917 |
|
|
261 |
|
Interest expense |
|
(27,776 |
) |
|
(36,003 |
) |
|
(56,934 |
) |
|
(72,338 |
) |
Other income (expense) |
|
3,010 |
|
|
(22 |
) |
|
6,159 |
|
|
(5,472 |
) |
Income before income taxes |
|
56,473 |
|
|
44,138 |
|
|
101,448 |
|
|
54,286 |
|
Income tax expense |
|
(16,180 |
) |
|
(17,113 |
) |
|
(19,502 |
) |
|
(22,068 |
) |
Net income |
$ |
40,293 |
|
$ |
27,025 |
|
$ |
81,946 |
|
$ |
32,218 |
|
Net income per share: |
|
|
|
|
|
|
|
|
||||
Net income per share, basic |
$ |
0.19 |
|
$ |
0.13 |
|
$ |
0.38 |
|
$ |
0.16 |
|
Weighted average shares of common stock outstanding, basic |
|
217,799 |
|
|
200,968 |
|
|
216,197 |
|
|
197,819 |
|
Net income per share, diluted |
$ |
0.18 |
|
$ |
0.13 |
|
$ |
0.37 |
|
$ |
0.16 |
|
Weighted average shares of common stock outstanding, diluted |
|
224,864 |
|
|
210,442 |
|
|
223,482 |
|
|
206,763 |
|
6
The following tables summarize our consolidated key performance measures, including Field contribution and Field contribution margin, which are non-GAAP measures, for the periods indicated:
|
For the three-month periods ended |
|
|
||||||||||
(dollars in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
Change |
|
% Change |
|
|
||||
Revenue |
$ |
670,483 |
|
$ |
589,553 |
|
$ |
80,930 |
|
|
13.7 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
451,958 |
|
|
378,753 |
|
|
73,205 |
|
|
19.3 |
% |
|
Gross margin |
$ |
218,525 |
|
$ |
210,800 |
|
$ |
7,725 |
|
|
3.7 |
% |
|
Gross margin percentage |
|
32.6 |
% |
|
35.8 |
% |
|
|
|
-3.2 |
% |
(1) |
|
Branch and regional administrative expenses |
|
97,079 |
|
|
90,069 |
|
|
7,010 |
|
|
7.8 |
% |
|
Field contribution |
$ |
121,446 |
|
$ |
120,731 |
|
$ |
715 |
|
|
0.6 |
% |
|
Field contribution margin |
|
18.1 |
% |
|
20.5 |
% |
|
|
|
|
|
||
Corporate expenses |
$ |
34,083 |
|
$ |
34,529 |
|
$ |
(446 |
) |
|
-1.3 |
% |
|
As a percentage of revenue |
|
5.1 |
% |
|
5.9 |
% |
|
|
|
|
|
||
Operating income |
$ |
79,980 |
|
$ |
80,034 |
|
$ |
(54 |
) |
|
-0.1 |
% |
|
As a percentage of revenue |
|
11.9 |
% |
|
13.6 |
% |
|
|
|
|
|
||
|
For the six-month periods ended |
|
|
||||||||||
(dollars in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
Change |
|
% Change |
|
|
||||
Revenue |
$ |
1,318,398 |
|
$ |
1,148,777 |
|
$ |
169,621 |
|
|
14.8 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
894,445 |
|
|
754,419 |
|
|
140,026 |
|
|
18.6 |
% |
|
Gross margin |
$ |
423,953 |
|
$ |
394,358 |
|
$ |
29,595 |
|
|
7.5 |
% |
|
Gross margin percentage |
|
32.2 |
% |
|
34.3 |
% |
|
|
|
-2.1 |
% |
(1) |
|
Branch and regional administrative expenses |
|
192,871 |
|
|
181,456 |
|
|
11,415 |
|
|
6.3 |
% |
|
Field contribution |
$ |
231,082 |
|
$ |
212,902 |
|
$ |
18,180 |
|
|
8.5 |
% |
|
Field contribution margin |
|
17.5 |
% |
|
18.5 |
% |
|
|
|
|
|
||
Corporate expenses |
$ |
68,239 |
|
$ |
72,034 |
|
$ |
(3,795 |
) |
|
-5.3 |
% |
|
As a percentage of revenue |
|
5.2 |
% |
|
6.3 |
% |
|
|
|
|
|
||
Operating income |
$ |
149,306 |
|
$ |
131,835 |
|
$ |
17,471 |
|
|
13.3 |
% |
|
As a percentage of revenue |
|
11.3 |
% |
|
11.5 |
% |
|
|
|
|
|
||
7
The following tables summarize our key performance measures by segment for the periods indicated:
|
PDS |
|
|
||||||||||
|
For the three-month periods ended |
|
|
||||||||||
(dollars and hours in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
Change |
|
% Change |
|
|
||||
Revenue |
$ |
553,929 |
|
$ |
486,012 |
|
$ |
67,917 |
|
|
14.0 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
394,047 |
|
|
328,078 |
|
|
65,969 |
|
|
20.1 |
% |
|
Gross margin |
$ |
159,882 |
|
$ |
157,934 |
|
$ |
1,948 |
|
|
1.2 |
% |
|
Gross margin percentage |
|
28.9 |
% |
|
32.5 |
% |
|
|
|
-3.6 |
% |
(4) |
|
Hours |
|
12,413 |
|
|
11,053 |
|
|
1,360 |
|
|
12.3 |
% |
|
Revenue rate |
$ |
44.62 |
|
$ |
43.97 |
|
$ |
0.65 |
|
|
1.7 |
% |
(1) |
Cost of revenue rate |
$ |
31.74 |
|
$ |
29.68 |
|
$ |
2.06 |
|
|
7.8 |
% |
(2) |
Spread rate |
$ |
12.88 |
|
$ |
14.29 |
|
$ |
(1.41 |
) |
|
-11.1 |
% |
(3) |
|
|
|
|
|
|
|
|
|
|
||||
|
HHH |
|
|
||||||||||
|
For the three-month periods ended |
|
|
||||||||||
(dollars and admissions/episodes in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
Change |
|
% Change |
|
|
||||
Revenue |
$ |
69,023 |
|
$ |
60,112 |
|
$ |
8,911 |
|
|
14.8 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
31,837 |
|
|
27,048 |
|
|
4,789 |
|
|
17.7 |
% |
|
Gross margin |
$ |
37,186 |
|
$ |
33,064 |
|
$ |
4,122 |
|
|
12.5 |
% |
|
Gross margin percentage |
|
53.9 |
% |
|
55.0 |
% |
|
|
|
-1.1 |
% |
(4) |
|
Home health total admissions (5) |
|
10.5 |
|
|
9.8 |
|
|
0.7 |
|
|
7.1 |
% |
|
Home health episodic admissions (6) |
|
8.5 |
|
|
7.3 |
|
|
1.2 |
|
|
16.4 |
% |
|
Home health total episodes (7) |
|
14.7 |
|
|
12.4 |
|
|
2.3 |
|
|
18.5 |
% |
|
Home health episodic mix (8) |
|
81.0 |
% |
|
74.5 |
% |
|
|
|
6.5 |
% |
(10) |
|
Home health revenue per completed episode (9) |
$ |
3,202 |
|
$ |
3,231 |
|
$ |
(29 |
) |
|
-0.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
||||
|
MS |
|
|
||||||||||
|
For the three-month periods ended |
|
|
||||||||||
(dollars and UPS in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
Change |
|
% Change |
|
|
||||
Revenue |
$ |
47,531 |
|
$ |
43,429 |
|
$ |
4,102 |
|
|
9.4 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
26,074 |
|
|
23,627 |
|
|
2,447 |
|
|
10.4 |
% |
|
Gross margin |
$ |
21,457 |
|
$ |
19,802 |
|
$ |
1,655 |
|
|
8.4 |
% |
|
Gross margin percentage |
|
45.1 |
% |
|
45.6 |
% |
|
|
|
-0.5 |
% |
(4) |
|
Unique patients served (“UPS”) |
|
95 |
|
|
91 |
|
|
4 |
|
|
4.4 |
% |
|
Revenue rate |
$ |
500.33 |
|
$ |
477.24 |
|
$ |
23.09 |
|
|
5.0 |
% |
(1) |
Cost of revenue rate |
$ |
274.46 |
|
$ |
259.64 |
|
$ |
14.82 |
|
|
6.0 |
% |
(2) |
Spread rate |
$ |
225.87 |
|
$ |
217.60 |
|
$ |
8.27 |
|
|
4.0 |
% |
(3) |
8
|
PDS |
|
|
||||||||||
|
For the six-month periods ended |
|
|
||||||||||
(dollars and hours in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
Change |
|
% Change |
|
|
||||
Revenue |
$ |
1,089,581 |
|
$ |
946,010 |
|
$ |
143,571 |
|
|
15.2 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
780,464 |
|
|
653,391 |
|
|
127,073 |
|
|
19.4 |
% |
|
Gross margin |
$ |
309,117 |
|
$ |
292,619 |
|
$ |
16,498 |
|
|
5.6 |
% |
|
Gross margin percentage |
|
28.4 |
% |
|
30.9 |
% |
|
|
|
-2.5 |
% |
(4) |
|
Hours |
|
24,469 |
|
|
21,940 |
|
|
2,529 |
|
|
11.5 |
% |
|
Revenue rate |
$ |
44.53 |
|
$ |
43.12 |
|
$ |
1.41 |
|
|
3.7 |
% |
(1) |
Cost of revenue rate |
$ |
31.90 |
|
$ |
29.78 |
|
$ |
2.12 |
|
|
7.9 |
% |
(2) |
Spread rate |
$ |
12.63 |
|
$ |
13.34 |
|
$ |
(0.71 |
) |
|
-5.9 |
% |
(3) |
|
|
|
|
|
|
|
|
|
|
||||
|
HHH |
|
|
||||||||||
|
For the six-month periods ended |
|
|
||||||||||
(dollars and admissions/episodes in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
Change |
|
% Change |
|
|
||||
Revenue |
$ |
135,632 |
|
$ |
116,845 |
|
$ |
18,787 |
|
|
16.1 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
62,670 |
|
|
53,041 |
|
|
9,629 |
|
|
18.2 |
% |
|
Gross margin |
$ |
72,962 |
|
$ |
63,804 |
|
$ |
9,158 |
|
|
14.4 |
% |
|
Gross margin percentage |
|
53.8 |
% |
|
54.6 |
% |
|
|
|
-0.8 |
% |
(4) |
|
Home health total admissions (5) |
|
21.5 |
|
|
19.5 |
|
|
2.0 |
|
|
10.3 |
% |
|
Home health episodic admissions (6) |
|
17.4 |
|
|
14.8 |
|
|
2.6 |
|
|
17.6 |
% |
|
Home health total episodes (7) |
|
29.6 |
|
|
24.5 |
|
|
5.1 |
|
|
20.8 |
% |
|
Home health episodic mix (8) |
|
80.9 |
% |
|
75.9 |
% |
|
|
|
5.0 |
% |
(10) |
|
Home health revenue per completed episode (9) |
$ |
3,185 |
|
$ |
3,193 |
|
$ |
(8 |
) |
|
-0.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
||||
|
MS |
|
|
||||||||||
|
For the six-month periods ended |
|
|
||||||||||
(dollars and UPS in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
Change |
|
% Change |
|
|
||||
Revenue |
$ |
93,185 |
|
$ |
85,922 |
|
$ |
7,263 |
|
|
8.5 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
51,311 |
|
|
47,987 |
|
|
3,324 |
|
|
6.9 |
% |
|
Gross margin |
$ |
41,874 |
|
$ |
37,935 |
|
$ |
3,939 |
|
|
10.4 |
% |
|
Gross margin percentage |
|
44.9 |
% |
|
44.2 |
% |
|
|
|
0.7 |
% |
(4) |
|
Unique patients served (“UPS”) |
|
188 |
|
|
180 |
|
|
8 |
|
|
4.4 |
% |
|
Revenue rate |
$ |
495.66 |
|
$ |
477.34 |
|
$ |
18.32 |
|
|
4.1 |
% |
(1) |
Cost of revenue rate |
$ |
272.93 |
|
$ |
266.59 |
|
$ |
6.34 |
|
|
2.5 |
% |
(2) |
Spread rate |
$ |
222.73 |
|
$ |
210.75 |
|
$ |
11.98 |
|
|
6.0 |
% |
(3) |
9
The following table reconciles gross margin and gross margin percentage to Field contribution and Field contribution margin:
|
For the three-month periods ended |
|
For the six-month periods ended |
|
||||||||
(dollars in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
July 4, 2026 |
|
June 28, 2025 |
|
||||
Gross margin |
$ |
218,525 |
|
$ |
210,800 |
|
$ |
423,953 |
|
$ |
394,358 |
|
Gross margin percentage |
|
32.6 |
% |
|
35.8 |
% |
|
32.2 |
% |
|
34.3 |
% |
Branch and regional administrative expenses |
|
97,079 |
|
|
90,069 |
|
|
192,871 |
|
|
181,456 |
|
Field contribution |
$ |
121,446 |
|
$ |
120,731 |
|
$ |
231,082 |
|
$ |
212,902 |
|
Field contribution margin |
|
18.1 |
% |
|
20.5 |
% |
|
17.5 |
% |
|
18.5 |
% |
Revenue |
$ |
670,483 |
|
$ |
589,553 |
|
$ |
1,318,398 |
|
$ |
1,148,777 |
|
The following table reconciles net income to EBITDA and Adjusted EBITDA:
|
|
For the three-month periods ended |
|
For the six-month periods ended |
|
||||||||
(dollars in thousands) |
|
July 4, 2026 |
|
June 28, 2025 |
|
July 4, 2026 |
|
June 28, 2025 |
|
||||
Net income |
|
$ |
40,293 |
|
$ |
27,025 |
|
$ |
81,946 |
|
$ |
32,218 |
|
Interest expense, net |
|
|
26,517 |
|
|
35,874 |
|
|
54,017 |
|
|
72,077 |
|
Income tax expense |
|
|
16,180 |
|
|
17,113 |
|
|
19,502 |
|
|
22,068 |
|
Depreciation and amortization |
|
|
2,849 |
|
|
2,617 |
|
|
5,893 |
|
|
5,211 |
|
EBITDA |
|
|
85,839 |
|
|
82,629 |
|
|
161,358 |
|
|
131,574 |
|
Goodwill, intangible and other long-lived asset impairment |
|
|
145 |
|
|
153 |
|
|
121 |
|
|
319 |
|
Non-cash share-based compensation |
|
|
4,135 |
|
|
5,159 |
|
|
8,282 |
|
|
16,155 |
|
Fees related to debt modifications |
|
|
1,504 |
|
|
- |
|
|
1,504 |
|
|
- |
|
Interest rate derivatives (1) |
|
|
(3,067 |
) |
|
(72 |
) |
|
(6,171 |
) |
|
5,523 |
|
Acquisition-related costs (2) |
|
|
4,390 |
|
|
3,400 |
|
|
7,500 |
|
|
3,507 |
|
Integration costs (3) |
|
|
1,246 |
|
|
2,269 |
|
|
2,669 |
|
|
2,543 |
|
Legal costs and settlements associated with acquisition matters (4) |
|
|
1,362 |
|
|
639 |
|
|
3,418 |
|
|
1,678 |
|
Restructuring (5) |
|
|
- |
|
|
80 |
|
|
- |
|
|
416 |
|
Other legal matters (6) |
|
|
3 |
|
|
(6,014 |
) |
|
28 |
|
|
(5,938 |
) |
Other adjustments (7) |
|
|
(122 |
) |
|
131 |
|
|
1,077 |
|
|
(50 |
) |
Total adjustments |
|
$ |
9,596 |
|
$ |
5,745 |
|
$ |
18,428 |
|
$ |
24,153 |
|
Adjusted EBITDA |
|
$ |
95,435 |
|
$ |
88,374 |
|
$ |
179,786 |
|
$ |
155,727 |
|
10
The following table reconciles net income to adjusted net income and presents adjusted net income per diluted share:
|
For the three-month periods ended |
|
For the six-month periods ended |
|
||||||||
(dollars in thousands, except share and per share data) |
July 4, 2026 |
|
June 28, 2025 |
|
July 4, 2026 |
|
June 28, 2025 |
|
||||
Net income |
$ |
40,293 |
|
$ |
27,025 |
|
$ |
81,946 |
|
$ |
32,218 |
|
Income tax expense |
|
16,180 |
|
|
17,113 |
|
|
19,502 |
|
|
22,068 |
|
Goodwill, intangible and other long-lived asset impairment |
|
145 |
|
|
153 |
|
|
121 |
|
|
319 |
|
Non-cash share-based compensation |
|
4,135 |
|
|
5,159 |
|
|
8,282 |
|
|
16,155 |
|
Fees related to debt modifications |
|
1,504 |
|
|
- |
|
|
1,504 |
|
|
- |
|
Interest rate derivatives (1) |
|
(3,067 |
) |
|
(72 |
) |
|
(6,171 |
) |
|
5,523 |
|
Acquisition-related costs (2) |
|
4,390 |
|
|
3,400 |
|
|
7,500 |
|
|
3,507 |
|
Integration costs (3) |
|
1,246 |
|
|
2,269 |
|
|
2,669 |
|
|
2,543 |
|
Legal costs and settlements associated with acquisition matters (4) |
|
1,362 |
|
|
639 |
|
|
3,418 |
|
|
1,678 |
|
Restructuring (5) |
|
- |
|
|
80 |
|
|
- |
|
|
416 |
|
Other legal matters (6) |
|
3 |
|
|
(6,014 |
) |
|
28 |
|
|
(5,938 |
) |
Other adjustments (7) |
|
(122 |
) |
|
131 |
|
|
1,077 |
|
|
(50 |
) |
Total adjustments |
|
25,776 |
|
|
22,858 |
|
|
37,930 |
|
|
46,221 |
|
Adjusted pre-tax income |
|
66,069 |
|
|
49,883 |
|
|
119,876 |
|
|
78,439 |
|
Income tax expense on adjusted pre-tax income (8) |
|
(16,517 |
) |
|
(12,471 |
) |
|
(29,969 |
) |
|
(19,610 |
) |
Adjusted net income |
$ |
49,552 |
|
$ |
37,412 |
|
$ |
89,907 |
|
$ |
58,829 |
|
Weighted average shares outstanding, diluted |
|
224,864 |
|
|
210,442 |
|
|
223,482 |
|
|
206,763 |
|
Adjusted net income per diluted share (9) |
$ |
0.22 |
|
$ |
0.18 |
|
$ |
0.40 |
|
$ |
0.28 |
|
The following footnotes are applicable to tables above that reconcile (i) net income to EBITDA and Adjusted EBITDA and (ii) net income to adjusted net income.
11
The following table reconciles net income to adjusted net income and presents adjusted net income per diluted share:
|
For the three-month periods ended |
|
For the six-month periods ended |
|
||||||||||||||||||||
|
July 4, 2026 |
|
June 28, 2025 |
|
July 4, 2026 |
|
June 28, 2025 |
|
||||||||||||||||
(dollars in thousands) |
Dollars |
|
Per Diluted Share |
|
Dollars |
|
Per Diluted Share |
|
Dollars |
|
Per Diluted Share |
|
Dollars |
|
Per Diluted Share |
|
||||||||
Net income |
$ |
40,293 |
|
$ |
0.18 |
|
$ |
27,025 |
|
$ |
0.13 |
|
$ |
81,946 |
|
$ |
0.37 |
|
$ |
32,218 |
|
$ |
0.16 |
|
Total adjustments (1) |
|
25,776 |
|
|
0.11 |
|
|
22,858 |
|
|
0.11 |
|
|
37,930 |
|
|
0.16 |
|
|
46,221 |
|
|
0.21 |
|
Income tax expense on adjusted pre-tax income |
|
(16,517 |
) |
|
(0.07 |
) |
|
(12,471 |
) |
|
(0.06 |
) |
|
(29,969 |
) |
|
(0.13 |
) |
|
(19,610 |
) |
|
(0.09 |
) |
Adjusted net income |
$ |
49,552 |
|
$ |
0.22 |
|
$ |
37,412 |
|
$ |
0.18 |
|
$ |
89,907 |
|
$ |
0.40 |
|
$ |
58,829 |
|
$ |
0.28 |
|
(1) Total adjustments agree to the net income to adjusted net income table above.
The table below reflects the increase or decrease, and aggregate impact, to the line items included on our consolidated statements of operations based upon the adjustments used in arriving at Adjusted EBITDA from EBITDA for the periods indicated.
|
For the three-month periods ended |
|
For the six-month periods ended |
|
||||||||
(dollars in thousands) |
July 4, 2026 |
|
June 28, 2025 |
|
July 4, 2026 |
|
June 28, 2025 |
|
||||
Cost of revenue, excluding depreciation and amortization |
$ |
345 |
|
$ |
(5,878 |
) |
$ |
(13 |
) |
$ |
(5,578 |
) |
Branch and regional administrative expenses |
|
1,485 |
|
|
1,599 |
|
|
3,504 |
|
|
4,837 |
|
Corporate expenses |
|
6,243 |
|
|
6,451 |
|
|
13,453 |
|
|
15,599 |
|
Acquisition-related costs |
|
4,390 |
|
|
3,400 |
|
|
7,500 |
|
|
3,506 |
|
Other operating expense |
|
- |
|
|
109 |
|
|
- |
|
|
47 |
|
Other income (expense) |
|
(2,867 |
) |
|
64 |
|
|
(6,016 |
) |
|
5,742 |
|
Total adjustments |
$ |
9,596 |
|
$ |
5,745 |
|
$ |
18,428 |
|
$ |
24,153 |
|
12
The following table reconciles the net cash provided by operating activities to free cash flow:
|
|
For the six-month period ended |
|
|
(dollars in thousands) |
|
July 4, 2026 |
|
|
Net cash provided by operations |
|
$ |
85,277 |
|
Purchases of property and equipment, and software |
|
|
(5,847 |
) |
Principal payments of term loans |
|
|
(3,312 |
) |
Principal payments of notes payable |
|
|
(4,961 |
) |
Settlements with swap counterparties |
|
|
4,268 |
|
Free cash flow |
|
$ |
75,425 |
|
13